American Society for Clinical Pathology (ASCP), College of American Pathologists (CAP), Association for Molecular Pathology (AMP), and American Society of Clinical Oncology (ASCO) have released a new, evidence-based clinical practice guideline on molecular marker testing for patients with colorectal carcinoma that identifies opportunities for improving patient outcomes.

 

This pivotal guideline addresses a wide range of molecular markers appropriate for testing in patients with early and advanced colorectal cancer. This guideline will aid in establishing standard molecular marker testing to help guide targeted therapy decisions, and advance personalized care for colorectal cancer patients.

 

Go here to access the paper.

 

Speaker: Antonia R. Sepulveda MD, PhD

Duration: 1.0 hr

Level of Instruction: Basic

 

CE Credit

AMA PRA Category 1 Credit(s)TM

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.

 

The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

 

This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP).

 

Note: CME/CMLE credit is available to all for $5 until October 2017. To continue receiving the discounted price after October, become an AMP member.

Course Information
Course Date:
March 31, 2017
Course Objectives
  • Discuss the recently published molecular testing guidelines for colorectal cancer.
  • Describe current laboratory practice guidelines for the use and performance of molecular testing in the evaluation of colorectal cancer.
  • Evaluate prognosis and prediction of response to therapies for the following markers: KRAS, NRAS, BRAF, PIK3CA, PTEN, DNA mismatch repair/microsatellite instability.
Molecular Biomarkers for the Evaluation of Colorectal Cancer
Speaker Information
Antonia R. Sepulveda MD, PhD  [ view bio ]
Individual topic purchase: Selected
American Medical Association
Continuing Medical Education: 1.00
American Society for Clinical Pathology
CMLE: 1.00
Products
Streaming
AMP Regular Member: $5.00
AMP Technologist Member: $5.00
AMP Associate Member: $5.00
Non-member Price: $5.00